Riyadh, Saudi Arabia
Riyadh, Saudi Arabia

Time filter

Source Type

The global immunohistochemistry (IHC) market is estimated to reach a value of USD 3.1 billion by 2025 The rising prevalence of cancer and increasing healthcare expenses driven by expanding aging population base are recognized to be the most influential factors driving the growth of the immunohistochemistry market. Furthermore, the rapid growth of biotech industry highlighted by increase in growth and revenue coupled with increase in stock market capitalization will nurture the growth. Cancer has high morbidity and mortality risk associated with them. The diagnosis of the disease is majorly dependent on the stage of the disease at admission. This has led to the high demand of immunohistochemistry products. IHC staining process is performed on cancer tissues to reveal the presence of HER2 receptors and/or hormone receptors on their surface. This information plays a vital role in planning the treatment for the disease, creating a demand for immunohistochemistry products. In addition, the rising popularity of targeted immunotherapy and biologic therapy for anticancer drug development and the increasing approvals of the same by the FDA to treat specific types of cancer are expected to benefit the growth in the long run. Other important factors driving growth include the alarming rise in healthcare spending and the shift in focus on value-based healthcare solutions. In 2015, the U.S. healthcare spending witnessed an increase of 5.8% to reach a value of USD 3.2 trillion. To curb the issue and establish a more value-based healthcare delivery, hospitals and care facilities are adopting a more specific and targeted therapy for better outcomes. Key Topics Covered: 1. Methodology and Scope 2. Executive Summary 3. Immunohistochemistry Market Variables, Trends & Scope 3.1. Market Segmentation & Scope 3.2. Immunohistochemistry: Market Dynamics 3.2.1. Market driver analysis 3.2.2. Market restraint analysis 3.3. Key Opportunities Prioritized 3.3.1. Key opportunities prioritized, by product 3.3.2. Key opportunities prioritized, by application 3.3.3. Key opportunities prioritized, by end-use 3.4. Immunohistochemistry - SWOT Analysis, By Factor (Political & legal, economic and technological) 4. Immunohistochemistry: Product Estimates & Trend Analysis 4.1. Immunohistochemistry Market: Product Movement Analysis 4.2. Antibodies 4.2.2. Primary Antibodies 4.2.3. Secondary Antibodies 4.3. Reagents 4.3.2. Histological Stains 4.3.3. Blocking Sera and Reagents 4.3.4. Chromogenic Substrates  4.3.5. Fixation Reagents 4.3.6. Stabilizers 4.3.7. Organic Solvents 4.3.8. Proteolytic Enzymes 4.3.9. Diluents 4.4. Equipment 4.4.2. Slide Staining Systems 4.4.3. Tissue Microarrays 4.4.4. Tissue Processing Systems 4.4.5. Slide Scanners 4.4.6. Others 4.5. Kits 5. Immunohistochemistry: Application Estimates & Trend Analysis 5.1. Immunohistochemistry Market: Application Movement Analysis 5.2. Diagnostics 5.2.2. Cancer 5.2.3. Infectious Diseases 5.2.4. Cardiovascular diseases 5.2.5. Autoimmune Diseases 5.2.6. Diabetes Mellitus 5.2.7. Nephrological Diseases 5.3. Drug Testing  6. Immunohistochemistry: End-Use Estimates & Trend Analysis 6.1. Immunohistochemistry Market: Application Movement Analysis 6.2. Hospitals and Diagnostic Laboratories 6.3. Research Institutes 6.4. Others 7. Immunohistochemistry: Regional Estimates & Trend Analysis, by Product, Application, and End-use 8. Competitive Landscape For more information about this report visit http://www.researchandmarkets.com/research/gkgmnp/immunohistochemist Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/31-billion-immunohistochemistry-ihc-market-analysis-and-forecast-segments-2014-2025-by-product-application--end-uses---research-and-markets-300455123.html


DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Point of Care Testing Market, by Product (Glucometers, BGE Analyzers, Pregnancy Tests, Infectious Diseases, etc.), Outlook 2022" report to their offering. It is predicted that by...


News Article | May 10, 2017
Site: globenewswire.com

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Thomas Lodise, Dr. Thomas Holland and Dr. William O’Riordan to the Clinical Advisory Board. The three new advisory board members are medical and scientific leaders in their fields: Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York and an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. His specific research objectives are to develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs.  He has published over 110 peer-reviewed articles and is an editorial board member for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.  He is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Thomas L. Holland, M.D., MSc-GH is an Assistant Professor at Duke University School of Medicine. Board certified in infectious disease, Dr. Holland has held a number of clinical positions at Duke University School of Medicine and is currently Assistant Professor in the Department of Infectious Diseases. With over 30 publications, Dr. Holland is an expert in antibacterial resistance with a focus on Gram-positive bacteria and is a member of ARLG. William D. O’Riordan, M.D. is the founder and CEO of eStudy Sites, one of the pre-eminent networks of clinical trial sites in the U.S. He is certified with the American Board of Emergency Medicine and is the lead investigator at the Chula Vista Research Site in California.  Dr. O’Riordan has held a number of clinical positions at the UCLA (University of California, Los Angeles) Medical Center and works at the Department of Emergency Medicine at the Sharp Chula Vista Medical Center. As a clinical trial investigator at the eStudy Site at the Chula Vista Research Site, he has overseen numerous clinical trials with antibacterial agents at all stages of clinical development. Dr. David Huang, CMO of Motif Bio, commented: “We are delighted to welcome these three outstanding scientific leaders to our Clinical Advisory Board. Each of them brings specific expertise that will be invaluable as we develop and prepare to commercialize iclaprim for patients with serious and life-threatening infections.” Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017. This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialize its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialization, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors” in Motif Bio plc’s Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.


— The IVD market in BRIC is expected to reach USD 15.71 billion by 2022 from USD 10.60 billion in 2017, at a CAGR of 8.2%. The key factors driving the growth of the market are growing patient awareness of personalized medicine, increasing prevalence of lifestyle and chronic diseases, growth in the number of private diagnostic centers, and improving healthcare system in emerging countries. However, market growth is restrained by the lack of reimbursement and the slow growth of the economy in some emerging countries. Browse 138 market data tables and 69 figures spread through 278 pages and in-depth TOC on "BRIC IVD Market by Product & Service (Instruments, Reagents, Software), Technology (Immunoassay, Hematology, Microbiology), Application (Diabetes, Cardiology, Infectious Diseases), Country (Brazil, Russia, India, China) - Forecast to 2022" In this report, the market is segmented by product & service, technology, application, end user, and country. Based on technology, the market is broadly segmented into immunoassays/immunochemistry, clinical chemistry, molecular diagnostics, hematology, clinical microbiology, coagulation & hemostasis, and other technologies. The molecular diagnostics segment is estimated to register the highest CAGR during the forecast period of 2017 to 2022. The rising prevalence of infectious diseases, cancer, and various genetic disorders; growing demand for blood screening; and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing is expected to drive the growth of the market during the forecast period. Based on application, the market is segmented into diabetes, infectious diseases, oncology/cancer, cardiology, HIV/AIDS, autoimmune diseases, nephrology, drug testing/pharmacogenomics, and others. The infectious diseases segment accounted for the largest share of the market in 2016, owing to the rising incidence of tuberculosis (TB), hepatitis, and hospital-acquired infections. Inquire for More info about IVD market Research Report At: https://goo.gl/wr3xT2 Geographically, China dominated the IVD market in BRIC in 2016. The large share of this country can be attributed to rising healthcare expenditure, increasing acceptance of personalized medicine, and increasing awareness towards technologically advanced products in this country. China is also expected to register the highest CAGR, due to the growth in research activities and increasing investments by leading players and government agencies in the country. Major players in the IVD market in BRIC and other emerging countries are Roche Diagnostics (Switzerland), Abbott Laboratories Inc. (U.S.), Siemens Healthineers (Germany), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Becton, Dickinson and Company (U.S.), Johnson & Johnson (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), QIAGEN N.V. (Germany), and Diasorin S.P.A. (Italy). • Detailed insights on all the submarkets, based on technology (immunoassays/immunochemistry, clinical chemistry, molecular diagnostics, hematology, clinical microbiology, coagulation & hemostasis, and other technologies), this can help market players to identify high growth segments in the IVD market in BRIC and other emerging countries • The report provides information on BRIC and other emerging countries such as Mexico, Turkey, Chile, Argentina, Colombia, South Korea, Indonesia, Malaysia, Thailand, and Saudi Arabia in this market. This can help the company to assess the competition across emerging countries in a better manner. • The report also provides information on key players in this market and their growth strategies and recent developments. This can help the company to assess the competition across BRIC and other emerging countries in a better manner. • Key insights and market sizing for the different end users of the IVD market namely, hospital-based laboratories, clinical/reference laboratories, academic institutes, point-of-care testing, patient self-testing, and other end users. • BRIC and other emerging country-wise market size and forecast for all the subsegments. The market size numbers provided in the report will also enable market players to identify key geographic markets, and thereby strategize their marketing efforts to achieve sustainable revenue growth in the coming years. • It provides key insights on market dynamics, such as drivers, restraints, opportunities, and challenges for this market. The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies for increasing their market shares. This report provides insights on the following pointers: • Market Penetration: Comprehensive information on the product portfolios offered by top players in the IVD market. The report analyzes the market by product type across the BRIC and other emerging countries • Product Development/Innovation: Detailed insights on upcoming trends, R&D activities, and product launches in the IVD market in BRIC and other emerging countries • Market Development: Comprehensive information on lucrative emerging markets, based on products & services, technology, application, end user, and country • Market Diversification: Exhaustive information about new products, growing countries, recent developments, and investments in the IVD market in BRIC and other emerging countries • Competitive Assessment: Growth strategies, products, distribution networks, and manufacturing capabilities of leading players in the IVD market in BRIC and other emerging countries Order a copy of IVD Market in BRIC by Product & Service (Instruments, Reagents, Software), Technology (Immunoassay, Hematology, Microbiology), Application (Diabetes, Cardiology, Infectious Diseases), Country (Brazil, Russia, India, China) - Forecast to 2022 Research Report At: http://www.rnrmarketresearch.com/contacts/purchase?rname=1001541 ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. For more information, please visit http://www.rnrmarketresearch.com/ivd-market-in-bric-by-product-service-instruments-reagents-software-technology-immunoassay-hematology-microbiology-application-diabetes-cardiology-infectious-diseases-country-brazil-russia-india-st-to-2022-market-report.html


It is predicted that by 2022 the global Point of Care Testing market will reach U$$ 30 Billion. The Point-of-care tests have immense potential to improve global health and to eventually reduce public and national spending on health. These devices have now found applications in a large number of medical conditions. Due to its increased usage in the field of critical care settings to deliver decentralized, patient-centric health care to the patients, the projections for the global Point of Care Testing market is expected to witness a rapid growth. The report Global Point of Care Testing Market, by Product (Glucometers, BGE Analyzers, Pregnancy Tests, Infectious Diseases, etc.), Outlook 2022 provides a detailed analysis of the current and future market scenario of the global market with a brief outlook of the IVD industry. The global Point of Care Testing market has been segmented on the basis of type of product. The major types of Point of Care Testing present in the market include glucose monitoring kits, blood gas and electrolyte analysers, pregnancy & fertility testing kits, cardiac markers, infectious diseases testing kits, and coagulation monitoring kits amongst others. According to the report, glucose monitoring kits is estimated to account for the largest share in 2016 due rising prevalence of diabetes & technological advancements in self-monitoring of blood glucose. Based on geography, the report divides the market into North America, Europe, Asia-Pacific, and Rest of the World. In 2016, North America is estimated to account for the largest share. The last section of the report discusses about the prominent players in global Point of Care Testing market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. 3.2 What is In Vitro Diagnostics? 5.1.2 Rising Use of Home Based Point of Care Diagnostics For more information about this report visit Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-30-billion-point-of-care-testing-glucometers-bge-analyzers-pregnancy-tests-infectious-diseases-market-outlook-2022---research-and-markets-300454249.html


News Article | May 10, 2017
Site: globenewswire.com

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Thomas Lodise, Dr. Thomas Holland and Dr. William O’Riordan to the Clinical Advisory Board. The three new advisory board members are medical and scientific leaders in their fields: Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York and an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. His specific research objectives are to develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs.  He has published over 110 peer-reviewed articles and is an editorial board member for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.  He is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Thomas L. Holland, M.D., MSc-GH is an Assistant Professor at Duke University School of Medicine. Board certified in infectious disease, Dr. Holland has held a number of clinical positions at Duke University School of Medicine and is currently Assistant Professor in the Department of Infectious Diseases. With over 30 publications, Dr. Holland is an expert in antibacterial resistance with a focus on Gram-positive bacteria and is a member of ARLG. William D. O’Riordan, M.D. is the founder and CEO of eStudy Sites, one of the pre-eminent networks of clinical trial sites in the U.S. He is certified with the American Board of Emergency Medicine and is the lead investigator at the Chula Vista Research Site in California.  Dr. O’Riordan has held a number of clinical positions at the UCLA (University of California, Los Angeles) Medical Center and works at the Department of Emergency Medicine at the Sharp Chula Vista Medical Center. As a clinical trial investigator at the eStudy Site at the Chula Vista Research Site, he has overseen numerous clinical trials with antibacterial agents at all stages of clinical development. Dr. David Huang, CMO of Motif Bio, commented: “We are delighted to welcome these three outstanding scientific leaders to our Clinical Advisory Board. Each of them brings specific expertise that will be invaluable as we develop and prepare to commercialize iclaprim for patients with serious and life-threatening infections.” Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017. This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialize its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialization, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors” in Motif Bio plc’s Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.


News Article | May 24, 2017
Site: www.eurekalert.org

A new study of malaria medicine quality in 8 sub-Saharan African countries has found a large and potentially growing market for non-quality-assured (QA) malaria treatments -- medicines not pre-approved by global health organisations - as much as 20% of the private-sector market in Kenya, and 42% in the Democratic Republic of Congo (DRC). As one of the most comprehensive recent studies relating to medicine quality in the region, the findings provide new insights for patients, researchers, policy makers and malaria control programmes because QA status is often linked to the quality of medicines - which can impact patient health and safety, malaria control efforts and artemisinin drug efficacy. The study, conducted in the private and public sectors of Benin, DRC, Kenya, Madagascar, Nigeria, Tanzania, Uganda and Zambia, was published today in a Malaria Journal article titled 'Do anti-malarials in Africa meet quality standards? The market penetration of non-quality assured artemisinin combination therapy in eight African countries'. Researchers measured the availability and market share of medicines not pre-approved under World Health Organization (WHO), Global Fund or European Medicines Agency (EMA) quality assurance programmes. Researchers collected data from 29 malaria medicine outlet surveys and audited more than 330,000 artemisinin-based combination therapies (ACTs) between 2009 and 2015. Based on samples from randomly selected clusters in the 8 countries, in 2014-15, non-QA medicines represented 42% and 27% of the private-sector market in Kinshasa and Katanga, respectively, 20% in Kenya, 19% in Uganda and Benin, 12% in Nigeria, 8% in Zambia and 5% in Tanzania. Moreover, non-QA medicines were available in 48% of private outlets in Nigeria, 38% in Uganda, 21% in Tanzania, 17% in Zambia and 83% and 53% in the Kinshasa and Katanga provinces of the DRC, respectively. In contrast with the private sector, the public-sector market share of non-QA medicines in 2014-15 was generally smaller - 6% in Nigeria, 5% in Kenya, and about 1% in Benin, Madagascar, Tanzania and Uganda. Due to limited regulatory capacities in many malaria-endemic countries, public health officials look to pre-approval status to help ensure medicine quality. Although approval status alone does not guarantee the safety of a medicine - in fact, non-QA treatments can be safe and effective in some cases - it does provide a strong, evidence-based indication of quality, the article states. Poor quality antimalarials include falsified medicines - or those produced fraudulently - and substandard medicines, which were improperly manufactured or have degraded over time. "These findings really improve our ability to understand the complex problem of medicine quality in Africa", said co-author Dr Megan Littrell, Principal Investigator at the ACTwatch project, which led the research collaboration. 'Although the data focus on quality-assurance status, it's hugely beneficial to know where non-QA antimalarials are most prevalent, particularly in countries with the highest malaria burdens, so that appropriate interventions can be considered alongside other efforts to tackle poor quality medicines". In addition to showing substantial market penetration and availability of non-QA antimalarials, the study states that most countries showed an increase in the private-sector market share of non-QA medicines between 2009 and 2015. The greatest increase occurred in Kenya and Kinshasa, where the market share approximately doubled, from 19% and 11% in 2009 to 42% and 20% in 2014-15, respectively. The public-sector non-QA market share mostly decreased during this time, except in Kenya, Kinshasa (DRC) and Zambia where the non-QA market share shifted from 1%, 1% and less than 1% in 2009, respectively, to 5%, 18% and 32% in 2014-15. "Non-QA antimalarials clearly have a strong market penetration across Africa, and these findings should help inform policy responses", said Professor Paul Newton, a co-author of the article and Head of the Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO). "However, we have also found numerous differences on the ground, so we must tailor our strategies for removing these medicines accordingly, by improving regulation, aligning national registration medicine lists with global standards, enhancing access to QA antimalarials and providing more support for manufacturers to ensure that their products are all quality assured. Frequent monitoring of the available antimalarials should be conducted to understand what patients are taking and the quality of the medications". The article, which included co-authors from the London School of Hygiene and Tropical Medicine, also found that diverse generics and formulations were available, but typically imported and distributed in urban areas at either pharmacies or drug stores. In countries such as Nigeria, over 90 unique manufacturers were found to be supplying non-QA medicines. In most cases, the private sector is the most common source of treatments, at for-profit health facilities, pharmacies, drug stores, general retailers, and mobile providers. However, patients also receive medicines from public-sector outlets, such as hospitals, clinics and other facilities. The WorldWide Antimalarial Resistance Network is a research partnership that provides comprehensive, timely, quality-assured evidence to help track the emergence and spread of malaria drug resistance, and improve the efficacy of existing antimalarial medicines and new drugs in development. This collaboration of research experts provides valuable evidence to help save more lives and support the global effort to control, eliminate and eventually eradicate malaria. The WWARN Antimalarial Quality (AQ) Surveyor helps to respond to some of the critical gaps in information. This mapping tool delivers customised summaries of published reports of antimalarial medicine quality across regions and over time. WWARN is a constituent organisation of the recently launched Infectious Diseases Data Observatory (IDDO), which takes a similar model to a range of devastating tropical and neglected illnesses, including Ebola. For further information, please visit http://www. (link is external) and http://www. (link is external). ACTwatch is a multi-country research project implemented by Population Services International (PSI). Launched in 2008 with funding from the Bill and Melinda Gates Foundation and with additional funding from UNITAID and the DFID, ACTwatch is designed to provide timely, relevant, and high-quality antimalarial and malaria diagnostic testing market intelligence. ACTwatch is implemented in 13 countries and employs standardized tools and approaches to provide comparable data across countries and over time. Research methods implemented include outlet and household surveys, supply chain studies, key informant interviews, and, in selected countries, a module to document private-sector fever case management practices using observation and client exit interviews. Since 2008, ACtwatch has implemented 50 outlet surveys, screened over 360,000 public- and private-sector outlets, and audited more than 400,000 antimalarials. Population Services International (PSI) is a global non-profit organization focused on the encouragement of healthy behaviour and affordability of health products. PSI was founded in 1970 to improve reproductive health using commercial marketing strategies and has expanded to work in over 50 countries in the areas of malaria, family planning, HIV, diarrhoea, pneumonia and sanitation. PSI has active malaria control programs in more than 35 countries worldwide, helping national ministries of health to scale up proven interventions, and sustain coverage over time. PSI focuses on a variety of interventions to improve availability, affordability and use of effective malaria prevention, diagnosis and treatment. These interventions include the delivery of long-lasting insecticidal treated nets (LLINs), artemisinin-based combination therapies (ACTs), rapid diagnostic tests (RDTs), strategic behaviour change communications and applied operational research. In 2015 alone, PSI delivered over 44 million LLINs, 11 million courses of ACT, and 9 million RDTs through public and private sectors. PSI also supports global malaria elimination goals by implementing test, treat and track strategies and strengthening national surveillance of malaria.


LONDON, May 23, 2017 /PRNewswire/ -- Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies Download the full report: https://www.reportbuyer.com/product/4882473/ Description Global Infectious Diseases Partnering 2010 to 2017 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Infectious Diseases partnering deals Financial deal terms for headline, upfront and royalty by stage of development Infectious Diseases partnering agreement structure Infectious Diseases partnering contract documents Top Infectious Diseases deals by value Most active Infectious Diseases dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals. The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates. Chapter 4 provides a review of the leading Infectious Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides comprehensive access to Infectious Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2010. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products. Report scope Global Infectious Diseases Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide. Global Infectious Diseases Partnering 2010 to 2017 includes: - Trends in Infectious Diseases dealmaking in the biopharma industry since 2010 - Analysis of Infectious Diseases deal structure - Access to headline, upfront, milestone and royalty data - Access to hundreds of Infectious Diseases deal contract documents - Comprehensive access to over 3500 Infectious Diseases deal records - The leading Infectious Diseases deals by value since 2010 - Most active Infectious Diseases dealmakers since 2010 The report includes deals for the following indications: Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications. Parasitic Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications In Global Infectious Diseases Partnering 2010 to 2017, available deals and contracts are listed by: - Headline value - Upfront payment value - Royalty rate value - Stage of development at signing - Deal component type - Technology type - Specific therapy indication Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Infectious Diseases Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,500 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are the sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Benefits Global Infectious Diseases Partnering 2010 to 2017 provides the reader with the following key benefits: - In-depth understanding of Infectious Diseases deal trends since 2010 - Access Infectious Diseases deal headline, upfront, milestone and royalty data - Research hundreds of actual contracts between Infectious Diseases partner companies - Comprehensive access to over 750 links to actual Infectious Diseases deals entered into by the world's biopharma companies - Indepth review of Infectious Diseases deals entered into by the top 25 most active dealmakers - Benchmark the key deal terms companies have agreed in previous deals - Identify key terms under which companies partner Infectious Diseases opportunities Download the full report: https://www.reportbuyer.com/product/4882473/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-infectious-diseases-partnering-2010---2017-deal-trends-players-and-financials-300462653.html


News Article | May 19, 2017
Site: www.chromatographytechniques.com

The majority of U.S. travelers who visit a doctor prior to traveling are already immune to measles, primarily from already receiving the appropriate vaccines. But more than half of the people who are not immune to the potentially-deadly measles germs are not vaccinated during that doctor’s visit, according to a new study in the journal Annals of Internal Medicine. “It was surprising to see such a high number of missed opportunities for MMR vaccination, even at these specialized pre-travel consultations,” said Emily Hyle, lead author, from the Massachusetts General Hospital Division of Infectious Diseases. The patient pool from 2009 to 2014 who had visited Global TravEpiNet clinics numbered 40,800. About 85 percent of those patients had immunity to measles. But 6,612 patients were eligible for the MMR vaccine. Fifty-three percent (3,477) were not vaccinated during that clinic visit. Some 48 percent of those non-vaccinations were due to patient refusal. Of those refusals, 74 percent of patients reported no concern about measles, 20 percent reported vaccine safety concerns, and cost worries accounted for the remaining six percent. Not all were refusals, however: 28 percent of the patients were not recommended the MMR by the health professionals at the clinic. Another 24 percent of the patients were simply referred to another doctor or location for the shots. Measles, which was declared eliminated from the U.S. in 2000, still appears domestically through importation where it is still regularly contagious, according to the paper. Sixty-one cases in the U.S. have been reported through April 22 for this year, according to CDC. The peak in recent years was 2014, when 667 cases were counted by the federal agency. That record year was driven by 383 cases reported among the Amish in Ohio, who are predominantly unvaccinated, and also from travelers from the Philippines, which had its own huge outbreak of the disease that year, according to federal data. “A single case of measles can spark a major outbreak, especially in communities where many people are not immune,” said Reinga LaRocque, the senior author. “Measles is one of the most infectious diseases known – 90 percent of people who are not immune will contract measles from an even-minimal exposure to somone who is infected.” But there is hope to improve coverage for everyone, Hyle said. “We can definitely improve how often providers specializing in pre-travel medical advice offer MMR vaccine to eligible travelers and encourage clear discussions with patients about the risks of contracting measles and of spreading the disease after their return to the U.S.,” she said.


News Article | May 26, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "North America Molecular Diagnostics Market (2016-2022)" report to their offering. Molecular Diagnostics are used to identify or monitor biomarkers associated with any particular diseases or conditions. Tests can also help in detecting and quantifying the presence of specific bacteria and viruses. These devices help surgeons in deciding that which therapy would work best on different patients. Molecular Diagnostics detect the diseases by analyzing RNA (Ribonucleic Acid) or DNA (Deoxyribonucleic Acid) in humans. These diagnostics are mainly used for clinical testing devices that are supplied in clinics, hospitals, laboratories, and research institutes. The Molecular Diagnostics Market is segmented on the basis of Product & Services, Technology, Application, End-user and Region. Based on Product & Services, the market is segmented into Instruments, Reagents & Kits, and software & services. Reagents & Kits are expected to gather the largest share in the market due to rising demand of reagents in clinical centers and diagnostics centers. Based on Technology, market is segmented into Polymerase Chain Reaction (PCR), Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), Hybridization, Microarray, DNA Sequencing and Next-Generation Sequencing. Based on Application, the market is segmented into six types such as Infectious diseases molecular testing, Molecular oncology testing, Inherited diseases molecular testing, Identity testing, Tissue type testing and Pharmacogenetics testing. Infectious Diseases includes Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG), Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hepatitis B, Hepatitis C, Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA) and other infectious diseases. On the other hand, oncology is further divided into Breast Cancer, Prostate Cancer, Colorectal Cancer and others. The infectious diseases molecular testing is mostly preferred in the hospitals and clinical centers. Based on End-User, the market is segmented into clinics, hospitals, laboratories, and research institutes. Based on Country, market is segmented into US, Canada and Mexico. For more information about this report visit http://www.researchandmarkets.com/research/vvb45v/north_america

Loading Infectious Diseases collaborators
Loading Infectious Diseases collaborators